The American Action Forum says "it is worthwhile to consider whether" there is a link between the implementation of 340B policies and upswings in retail drug spending. A drug policy experts who found that that inflation penalties in the 340B program were associated with lower annual drug price increases says AAF's analysis "is specious at best."

GOP-aligned Think Tank Alleges that 340B Expansions Contributed to Drug Spending Spurts

An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs whose research has found that 340B inflation penalties restrain drug price growth.

AAF, a think tank closely-aligned with the congressional Republican leadership and the pharmaceutical industry, published the analysis online on May 13. It “examines how retail spending per capita on prescription drugs has correlated with the introduction and expansion of the MDRP and 340B program, with specific emphasis on the 340B program,” AAF Health Care Policy Analyst Jackson Hammond wrote.

An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs whose research has found that 340B inflation penalties restrain drug price growth.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer